|
Código del ensayo 79635322MMY3001 - TRIlogy 4 |
|
Ensayo A phase 3 randomized study comparing jnj-79635322 and an anti-bcmaxcd3 bispecific antibody in participants with relapsed or refractory multiple myeloma who have received at least 3 prior lines of therapy including a pi, an imid, and an anti-cd38 antibody |
|
Estado Abierto a inclusión |
|
Localización Tumoral Hematológicos |
|
Tipo de tumor Mielomas |
|
Tipo de ensayo Ensayo de Fase III |
|
Tipo de tratamiento |
|
Situación clínica |
|
Centro |
